Institute for Translational Medicine, Medical School, University of Pecs, 12 Szigeti street, H-7624 Pecs, Hungary.
Institute for Translational Medicine, Medical School, University of Pecs, 12 Szigeti street, H-7624 Pecs, Hungary; Centre for Translational Medicine, Semmelweis University, 26 Ulloi street, H-1085 Budapest, Hungary; Division of Pancreatic Diseases, Semmelweis University, 23-26 Baross street, H-1085 Budapest, Hungary.
Ageing Res Rev. 2024 Jan;93:102164. doi: 10.1016/j.arr.2023.102164. Epub 2023 Dec 14.
The prognostic significance of obesity in sarcopenic adults is controversial. This systematic review and meta-analysis aimed to investigate the effect of additional obesity on health outcomes in sarcopenia. MEDLINE, EMBASE, Scopus and CENTRAL were systematically searched for studies to compare health outcomes of adults with sarcopenic obesity (SO) to those of sarcopenic non-obese (SNO) adults. We also considered the methods of assessing obesity. Of 15060 records screened, 65 papers were included (100612 participants). Older community-dwelling SO adults had 15% lower mortality risk than the SNO group (hazard ratio, HR: 0.85, 95% confidence interval 0.76, 0.94) even when obesity was assessed by measurement of body composition. Additionally, meta-regression analysis revealed a significant negative linear correlation between the age and the HR of all-cause mortality in SO vs. SNO community-dwelling adults, but not in severely ill patients. Compared with SNO, SO patients presented lower physical performance, higher risk for metabolic syndrome, but similar cognitive function, risk of falls and cardiovascular diseases. Age-related obesity, SO and later fat loss leading to SNO represent consecutive phases of biological aging. Additional obesity could worsen the health state in sarcopenia, but above 65 years SO represents a biologically earlier phase with longer life expectancy than SNO.
肥胖在肌少症成年人中的预后意义存在争议。本系统评价和荟萃分析旨在研究额外肥胖对肌少症健康结局的影响。系统检索了 MEDLINE、EMBASE、Scopus 和 CENTRAL 以比较肌少症合并肥胖(SO)和单纯肌少症(SNO)成年人的健康结局。我们还考虑了评估肥胖的方法。在筛选出的 15060 条记录中,有 65 篇论文被纳入(100612 名参与者)。与 SNO 组相比,年龄较大的社区居住 SO 成年人的死亡率降低了 15%(风险比,HR:0.85,95%置信区间 0.76,0.94),即使肥胖是通过身体成分测量来评估的。此外,元回归分析显示,SO 与 SNO 社区居住成年人全因死亡率的 HR 与年龄之间存在显著负线性相关性,但在重病患者中则没有。与 SNO 相比,SO 患者的身体机能较低,代谢综合征风险较高,但认知功能、跌倒风险和心血管疾病相似。与年龄相关的肥胖、SO 和随后的脂肪损失导致 SNO 代表了生物衰老的连续阶段。额外的肥胖可能会使肌少症的健康状况恶化,但 65 岁以上的 SO 代表了一个更早的生物学阶段,比 SNO 有更长的预期寿命。
Cochrane Database Syst Rev. 2016-8-22
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2017-12-22
J Cachexia Sarcopenia Muscle. 2025-6
Arch Endocrinol Metab. 2025-4-11